| Ticker: | SKYE |
| Current Price: | $1.09 |
| % Daily Change: | 0.93% |
| Volume (1,000s): | 65.16 |
| Average Volume (1,000s): | 165.30 |
| Market Cap (M): | $4.83 |
| 1/2/2024 Price: | $2.72 |
| Change Since Inception: | -59.93% |
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130
United States
Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).